SynthesisBrain injury2017
The danger zone: Systematic review of the role of HMGB1 danger signalling in traumatic brain injury.
Synthesis in Brain injury, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Interleukin-6 as a prognostic biomarker of clinical outcomes after traumatic brain injury: a systematic review.Neurosurgical review · 2022Pooled it
- Review
- Evidence-Based Interventions for Functional Restoration and Pain Management following Traumatic Brain Injury.Archives of clinical and medical case reports · 2026Article
- Blast injury leads to chronic shifts in protein expression of distinct astrocyte populations.Brain communications · 2026Article
- Isolation of Primary Brain Cells: Challenges and Solutions.Archives of clinical and biomedical research · 2025Article
- Association Between Metabolic and Inflammatory Biomarkers and Prognosis in Traumatic Brain Injury: A Focus on Short- and Medium-Term Mortality.Journal of inflammation research · 2025Article
- 'Comprehensive review of emerging drug targets in traumatic brain injury (TBI): challenges and future scope.Inflammopharmacology · 2024Review
- Epidemiology, Pathophysiology, and Treatment Strategies of Concussions: A Comprehensive Review.Fortune journal of health sciences · 2024Article
- The Renin Angiotensin System as a Therapeutic Target in Traumatic Brain Injury.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Review
- A Swine Model of Changes in the Neuronal Electromagnetic Field After Traumatic Brain Injury: A Pilot Study.Cureus · 2023Article
- A mechanistic review of pharmacological activities of homeopathic medicine licorice against neural diseases.Frontiers in neuroscience · 2023Review
- Astrocytes as a target for therapeutic strategies in epilepsy: current insights.Frontiers in molecular neuroscience · 2023Review
- Neuroinflammatory Biomarkers for Traumatic Brain Injury Diagnosis and Prognosis: A TRACK-TBI Pilot Study.Neurotrauma reports · 2023Article
- Chronic cerebral aspects of long COVID, post-stroke syndromes and similar states share their pathogenesis and perispinal etanercept treatment logic.Pharmacology research & perspectives · 2022Review
- Fast Maturation of Splenic Dendritic Cells Upon TBI Is Associated With FLT3/FLT3L Signaling.Frontiers in immunology · 2022Article
- Genetic inhibition of RIPK3 ameliorates functional outcome in controlled cortical impact independent of necroptosis.Cell death & disease · 2021Article
- LPS Primes Brain Responsiveness to High Mobility Group Box-1 Protein.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Bidirectional Brain-Systemic Interactions and Outcomes After TBI.Trends in neurosciences · 2021Review
- Disulfide HMGB1 acts via TLR2/4 receptors to reduce the numbers of oligodendrocyte progenitor cells after traumatic injury in vitro.Scientific reports · 2021Article
- Broader Insights into Understanding Tumor Necrosis Factor and Neurodegenerative Disease Pathogenesis Infer New Therapeutic Approaches.Journal of Alzheimer's disease : JAD · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundTraumatic brain injuries (TBI) are associated with complex inflammatory pathways that lead to the development of secondary injuries such as cerebral ischaemia, elevated intracranial pressure and cognitive deficits. The association between intracellular danger signalling involving nuclear chromatin-binding factor, high mobility group box-1 (HMGB1) and inflammatory pathways following TBI has not yet been fully understood. PRIMARY
objectiveTo comprehensively review the available literature regarding the potential diagnostic, prognostic and therapeutic use of HMGB1 in TBI.
methodsA systematic literature review of studies available in PubMed using human and animal subjects was performed. A total of eight studies were included in the results.
conclusionsA comprehensive review of these reports demonstrated that, following TBI, HMGB1 is released from damaged neurons and is elevated in patient's serum and CSF. Furthermore, these studies showed the potential for HMGB1 to serve as a prognostic biomarker and therapeutic target in patients with TBI. Thus, HMGB1 is a prospective candidate for future studies as it shows promise in treating and/or predicting the sequelae of TBI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.